Stemetil Dosing for Acute Vertigo in Meniere's Disease
For acute vertigo attacks in Meniere's disease, use Stemetil (prochlorperazine) 5-10 mg orally 3-4 times daily, with a maximum of 40 mg per day, for a limited course only during active attacks. 1, 2
Important Clarification on Terminology
There appears to be confusion in the question - "Stemetil" typically refers to prochlorperazine, not cinnarizine. These are different medications:
- Stemetil (prochlorperazine): A phenothiazine antiemetic/vestibular suppressant
- Cinnarizine: A calcium channel blocker with antihistamine properties (brand names include Stugeron)
Dosing Algorithm for Acute Meniere's Attacks
For Prochlorperazine (Stemetil):
- Initial dose: 5 mg orally 3-4 times daily 2
- Alternative: 10 mg orally 3-4 times daily for more severe symptoms 2
- Maximum daily dose: 40 mg (higher doses only for resistant cases) 2
- Duration: Limited course during acute attacks only - not for continuous use 1
If Using Cinnarizine Instead:
- Standard dose: 75 mg twice daily (150 mg total per day) 3
- Alternative regimen: 20 mg cinnarizine combined with 40 mg dimenhydrinate, three times daily 4, 5
Clinical Context and Guideline Recommendations
The 2020 American Academy of Otolaryngology-Head and Neck Surgery guidelines recommend offering vestibular suppressants for symptomatic management of vertigo only during acute Meniere's disease attacks, not for continuous prophylaxis. 1 This is critical - these medications should not be used long-term as they can interfere with central vestibular compensation.
Key Prescribing Principles:
- Timing matters: Vestibular suppressants work best when given during the acute attack (which lasts 20 minutes to 12 hours by definition) 1
- Short-term use only: These medications are for acute symptom relief, not prevention 1
- No evidence for superiority: There is insufficient evidence demonstrating that any specific vestibular suppressant class is superior to another 1
Important Caveats and Safety Considerations
For Prochlorperazine:
- Elderly patients: Start with lower doses and increase gradually; elderly are more susceptible to hypotension and extrapyramidal reactions 2
- Anticholinergic effects: Expect blurred vision, dry mouth, dilated pupils, urinary retention, and sedation 1
- Extrapyramidal reactions: Monitor for dystonic reactions, particularly in younger patients 2
Common Pitfall to Avoid:
Do not prescribe vestibular suppressants for continuous daily use in Meniere's disease. The guidelines explicitly state these should be limited to acute attacks only 1. Continuous use can:
- Delay central vestibular compensation
- Lead to medication dependence (especially with benzodiazepines) 1
- Cause significant anticholinergic side effects with prolonged use 1
Evidence Quality Note
The evidence for pharmacological interventions in Meniere's disease is generally low to very low certainty 6. A 2023 Cochrane review found insufficient high-quality evidence to definitively recommend any specific systemic pharmacological intervention, though vestibular suppressants remain guideline-recommended for acute symptom management 6. The 2020 AAO-HNS guidelines base their recommendation on nonrandomized studies and observational data, with a preponderance of benefit over harm for acute use 1.
Alternative Considerations
If cinnarizine is actually intended, the evidence shows modest benefit at 75 mg twice daily, though results were "less conclusive" specifically for Meniere's disease compared to other vestibular disorders 3. A fixed combination of cinnarizine 20 mg plus dimenhydrinate 40 mg three times daily showed efficacy in reducing vertigo symptoms, though this was not specific to Meniere's disease 4, 5.